Switzerland-based Myovant announced an 88 percent one-year response rate in the positive Phase III LIBERTY extension study of once-daily, oral relugolix combination therapy in women with heavy menstrual bleeding associated with uterine fibroids.
Shares of Biohaven Pharmaceutical Holding Company Ltd. fell 16 percent after the company’s treatment for anxiety disorder failed to meet the main goal in a late-stage study.
Researchers with the Abramson Cancer Center of the University of Pennsylvania, led by Carl June, published results from the first U.S. Phase I trial of CRISPR-Cas9-edited T-cells in humans with advanced cancer.
Emeryville, California-based Zogenix announced positive topline data from the company’s Phase III trial of Fintepla (fenfluramine) in Lennox-Gastaut Syndrome.
Biogen successfully fended off a patent challenge from generic company Mylan over the multiple sclerosis (MS) drug Tecfidera.
Genentech’s Risdiplam showed significant improvement in motor function in people aged 2-25 who have been diagnosed with Type 2 or 3 spinal muscular atrophy.
Regeneron Pharmaceuticals Inc. is ramping up efforts to develop a set of coronavirus treatments, which could be available for testing or use in some patients within a few months, the drugmaker said on Thursday.
A new business direction was approved by the board of directors for Lund, Sweden-based Active Biotech.
An international team of researchers led by the University of Manchester developed a new antiviral using natural glucose derivatives called cyclodextrins – a type of sugar – which shows promise in treating a broad range of viruses including herpes simplex, respiratory syncytial virus, hepatitis C, HIV and Zika virus.
Drug development accelerator BioMotiv and Bristol-Myers Squibb jointly launched Anteros Pharmaceuticals, which will focus on developing a new class of medicines for fibrotic and inflammatory diseases.
